Srigiridhar Kotamraju

Title: Srigiridhar Kotamraju: Innovator in Anti-Cancer Research

Introduction

Srigiridhar Kotamraju is a notable inventor based in Telangana, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that serve as selective HDAC inhibitors and anti-cancer agents. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Kotamraju's latest patents include innovative compounds that have shown promise in the fight against cancer. One of his patents focuses on indole (sulfomyl) n-hydroxy benzamide derivatives, which act as selective HDAC inhibitors. These compounds are characterized by a general formula that includes various aryl, heteroaryl, and alkyl groups, making them versatile in their application. Another significant patent involves C5, C6 substituted and/or fused oxindole compounds, which are described as effective anti-cancer agents. The detailed processes for preparing these compounds highlight their potential in therapeutic applications.

Career Highlights

Srigiridhar Kotamraju is affiliated with the Council of Scientific & Industrial Research, where he continues to engage in groundbreaking research. His work is instrumental in developing new therapeutic strategies that could significantly impact cancer treatment.

Collaborations

Kotamraju has collaborated with esteemed colleagues such as Chandrasekhar Srivari and Prathama Satyendra Mainkar. These collaborations enhance the research efforts and contribute to the innovative environment in which he works.

Conclusion

Srigiridhar Kotamraju's contributions to medicinal chemistry and cancer research are noteworthy. His patents reflect a commitment to developing effective treatments that could change the landscape of cancer therapy.